Structural and quantum chemical studies of 8-aryl-sulfanyl adenine class Hsp90 inhibitors

Journal of Medicinal Chemistry

Volumn 49, Issue 16, 2006, Pages 4953-4960

  Immormino, Robert M ^a,b   Kang, Yanlong ^c   Chiosis, Gabriela ^c   Gewirth, Daniel T ^a,b  

^a HAUPTMAN WOODWARD MEDICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE DERIVATIVE; ANTINEOPLASTIC AGENT; BROMINE; CHAPERONE; CHLORINE; HALIDE; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; IODINE; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PU H64; PU H71;

AMINO TERMINAL SEQUENCE; ARTICLE; CALCULATION; COMPLEX FORMATION; CRYSTALLIZATION; DRUG BINDING SITE; DRUG CONFORMATION; DRUG PROTEIN BINDING; HYDROGEN BOND; IC 50; LIGAND BINDING; PROTEIN DOMAIN; QUANTUM CHEMISTRY; SIGNAL TRANSDUCTION; STEREOSPECIFICITY; STRUCTURE ACTIVITY RELATION; X RAY CRYSTALLOGRAPHY;

ADENINE; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; OXIDATION-REDUCTION; QUANTUM THEORY; SOLUTIONS; SULFANILIC ACIDS;

EID: 33746914732     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060297x     Document Type: Article

References (45)

1. Maloney, A.; Workman, P. HSP90 as a new therapeutic target for cancer therapy: the story unfolds. Expert Opin. Biol. Ther. 2002, 2, 3-24.
2. Pearl, L. H. Hsp90 and Cdc37-a chaperone cancer conspiracy. Curr. Opin. Genet. Dev. 2005, 15, 55-61.
3. McLaughlin, S. H.; Ventouras, L. A.; Lobbezoo, B.; Jackson, S. E. Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform. J. Mol. Biol. 2004, 344, 813-826.
4. Richter, K.; Walter, S.; Buchner, J. The Co-chaperone Sba1 connects the ATPase reaction of Hsp90 to the progression of the chaperone cycle. J. Mol. Biol. 2004, 342, 1403-1413.
5. Dollins, D. E.; Immormino, R. M.; Gewirth, D. T. Structure of unliganded GRP94, the endoplasmic reticulum Hsp90: Basis for nucleotide-induced conformational change. J. Biol Chem. 2005, 280, 30438-30447.
6. Immormino, R. M.; Dollins, D. E.; Shaffer, P. L.; Soldano, K. L.; Walker, M. A.; et al. Ligand-induced conformational shift in the N-terminal domain of GRP94, an Hsp90 chaperone. J. Biol. Chem. 2004, 279, 46162-46171.
7. Prodromou, C.; Roe, S. M.; O'Brien, R.; Ladbury, J. E.; Piper, P. W.; et al. Identification and structural characterization of the ATP/ ADP-binding site in the Hsp90 molecular chaperone. Cell 1997, 90, 65-75.
8. Marcu, M. G.; Chadli, A.; Bouhouche, I.; Catelli, M.; Neckers, L. M. The heat shock protein 90 antagonist novobiocin interacts with a previously unrecognized ATP-binding domain in the carboxyl terminus of the chaperone. J. Biol. Chem. 2000, 275, 37181-37186.
9. Cliff, M. J.; Williams, M. A.; Brooke-Smith, J.; Barford, D.; Ladbury, J. E. Molecular recognition via coupled folding and binding in a TPR domain. J. Mol. Biol. 2005, 346, 717-732.
10. Pratt, W. B. The hsp90-based chaperone system: involvement in signal transduction from a variety of hormone and growth factor receptors. Proc. Soc. Exp. Biol. Med. 1998, 217, 420-434.
11. Huai, Q.; Wang, H.; Liu, Y.; Kim, H. Y.; Toft, D.; et al. Structures of the N-terminal and middle domains of E. coli Hsp90 and conformation changes upon ADP binding. Structure (London) 2005, 13, 579-590.
12. Meyer, P.; Prodromou, C.; Hu, B.; Vaughan, C.; Roe, S. M.; et al. Structural and functional analysis of the middle segment of hsp90. Implications for ATP hydrolysis and client protein and cochaperone interactions. Mol. Cell 2003, 11, 647-658.
13. Chiosis, G.; Vilenchik, M.; Kim, J.; Solit, D. Hsp90: the vulnerable chaperone. Drug Discovery Today 2004, 9, 881-888.
14. Pratt, W. B.; Toft, D. O. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. (Maywood, NJ, U.S.) 2003, 228, 111-133.
15. Shao, J.; Grammatikakis, N.; Scroggins, B. T.; Uma, S.; Huang, W.; et al. Hsp90 regulates p50(cdc37) function during the biogenesis of the active conformation of the heme-regulated eIF2 alpha kinase. J. Biol. Chem. 2001, 276, 206-214.
16. Schulte, T. W.; An, W. G.; Neckers, L. M. Geldanamycin-induced destabilization of Raf-1 involves the proteasome. Biochem. Biophys. Res. Commun. 1997, 239, 655-659.
17. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
18. Matsumoto, Y.; Machida, H.; Kubota, N. Preferential sensitization of tumor cells to radiation by heat shock protein 90 inhibitor geldanamycin. J. Radiat. Res. (Tokyo) 2005, 46, 215-221.
19. Sausville, E. A.; Tomaszewski, J. E.; Ivy, P. Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr. Cancer Drug Targets 2003, 3, 377-383.
20. Blagosklonny, M. V.; Fojo, T.; Bhalla, K. N.; Kim, J. S.; Trepel, J. B.; et al. The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001, 15, 1537-1543.
21. Neckers, L.; Schulte, T. W.; Mimnaugh, E. Geldanamycin as a potential anti-cancer agent: its molecular target and biochemical activity. Invest. New Drugs 1999, 17, 361-373.
22. Schulte, T. W.; Akinaga, S.; Soga, S.; Sullivan, W.; Stensgard, B.; et al. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin. Cell Stress Chaperones 1998, 3, 100-108.
23. Wright, L.; Barril, X.; Dymock, B.; Sheridan, L.; Surgenor, A.; et al. Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms. Chem. Biol. 2004, 11, 775-785.
24. Chiosis, G.; Timaul, M. N.; Lucas, B.; Munster, P. N.; Zheng, F. F.; et al. A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells. Chem. Biol. 2001, 8, 289-299.
25. Vilenchik, M.; Solit, D.; Basso, A.; Huezo, H.; Lucas, B.; et al. Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90. Chem. Biol. 2004, 11, 787-797.
26. Chiosis, G.; Lucas, B.; Shtil, A.; Huezo, H.; Rosen, N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of Her2 tyrosine kinase. Bioorg. Med. Chem. 2002, 10, 3555-3564.
27. Biamonte, M. A.; Shi, J.; Hong, K.; Hurst, D. C.; Zhang, L.; et al. Orally active purine-based inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 817-828.
28. Kamal, A.; Thao, L.; Sensintaffar, J.; Zhang, L.; Boehm, M. F.; et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003, 425, 407-410.
29. Dymock, B. W.; Barril, X.; Brough, P. A.; Cansfield, J. E.; Massey, A.; et al. Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design. J. Med. Chem. 2005, 48, 4212-4215.
30. Shen, G.; Blagg, B. S. Radester, a novel inhibitor of the Hsp90 protein folding machinery. Org. Lett. 2005, 7, 2157-2160.
31. Clevenger, R. C.; Blagg, B. S. Design, synthesis, and evaluation of a radicicol and geldanamycin chimera, radamide. Org. Lett. 2004, 6, 4459-4462.
32. Cheung, K. M.; Matthews, T. P.; James, K.; Rowlands, M. G.; Boxall, K. J.; et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 3338-3343.
33. Kreusch, A.; Han, S.; Brinker, A.; Zhou, V.; Choi, H. S.; et al. Crystal structures of human HSP90alpha-complexed with dihydroxyphenyl-pyrazoles. Bioorg. Med. Chem. Lett. 2005, 15, 1475-1478.
34. Chene, P. ATPases as drug targets: learning from their structure. Nat. Rev. Drug Discovery 2002, 1, 665-673.
35. Llauger, L.; He, H.; Kim, J.; Aguirre, J.; Rosen, N.; et al. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90. J. Med. Chem. 2005, 48, 2892-2905.
36. He, H.; Zatorska, D.; Kim, J.; Aguirre, J.; Llauger, L.; et al. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J. Med. Chem. 2006, 49, 381-390.
37. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795-800.
38. Jones, T. A.; Zou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for binding protein models in electron density maps and the location of errors in these models. Acta Crystallogr., Sect. A 1991, 47, 110-119.
39. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; et al. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr., Sect. D 1998, 54, 905-921.
40. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr., Sect. D 2004, 60, 1355-1363.
41. Richardson, J. S.; Arendall, W. B., 3rd; Richardson, D. C. New Tools and Data for Improving Structures, Using All-Atom Contacts. Methods in Enzymology. Academic Press: San Diego, CA, 2003; pp 385-412.
42. Lovell, S. C.; Davis, I. W.; Arendall, W. B., 3rd; de Bakker, P. I.; Word, J. M.; et al. Structure validation by Calpha geometry: phi, psi and Cbeta deviation. Proteins 2003, 50, 437-450.
43. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
44. Prodromou, C.; Roe, S. M.; Piper, P. W.; Pearl, L. H. A molecular clamp in the crystal structure of the N-terminal domain of the yeast Hsp90 chaperone. Nat. Struct. Biol. 1997, 4, 477-482.
45. Berman, H. M.; Bhat, T. N.; Bourne, P. E.; Feng, Z.; Gilliland, G.; et al. The Protein Data Bank and the challenge of structural genomics. Nat. Struct. Biol. 2000, 7, 957-959.